Cardiovascular Trials and Other Research Studies

Through the approval of the Broward Health Institutional Review Board, Broward Health Medical Center offers pharmaceutical-sponsored FDA-approved cardiovascular clinical trials to the community. These various pharmaceutical sponsored trials involve cutting-edge cardiovascular related areas to study cardiac disease, anticoagulants or antithrombotics, blood pressure control, cholesterol control, atrial fibrillation, interventional and cardiology, and diabetes, as well as cardiac device trials.

Cardiovascular clinical trial research is done to help doctors to find a better way to treat and diagnose patients with cardiac disease. The decision to enroll in a clinical trial is completely voluntary. Each trial offers its own opportunities and risks, but many research volunteers find that clinical trials offer these common benefits:

• opportunity for health care provided by leading physicians in the field of cardiac research
• access to new drugs and interventions before they are widely available
• for you to have a more active role in your own health care
• close monitoring of your health care and any side effects
• you may be the first to benefit, if the approach being studied is found to be helpful to the disease being studied
• an opportunity to make a valuable contribution to cardiac research

Please review the following clinical trials, and if you think that you may qualify and may wish to participate you can call the senior research nurses at the cardiovascular research department. Please call Broward Health Medical Center Cardiovascular Research and leave your name and number to 954-468-5237 along with the study name that you think that you may qualify for and a research nurse will contact you.

For further information, please visit: http://www.clinicaltrials.gov/

Clinical Trials List

December 18, 2012 - The following trials are open for enrollment to new patients:

STOP-AF Post-Approval Study:  Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study   (Medtronic) Sponsor: MEDTRONIC Investigator: Dr. Ahmed Osman

ISIS-ICD:  ITSY09 - Inappropriate Shocks Reduction wIth PARAD+ Dual-chamber DiScrimination (ISIS-ICDStudy) Sponsor: SORIN Investigator: Dr. Ahmed Osman

REDUCE-IT: AMR-01-01-0019 - A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial) Sponsor: ANTHERA Investigator: Dr. Joel Gellman

RIVER-PCI: GS-US-259-0116 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization Sponsor: GILEAD Investigator: Dr. Violet Atanasoski-McCormack

PEGASUS TIMI 54: D5132C00001 - A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction Sponsor: ASTRAZENECA Investigator: Dr. Arnoux Blanchard

There are no open studies at this time.

Please call the Principal Investigator or Study coordinator with any questions or potential subjects.